TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29600595

Group type: EXPERIMENTAL
Intervention: Daily oral tablets
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Monthly vaginal ring
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Monthly intramuscular injections
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: TRIO products (all forms)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Placebo delivery forms (overall)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Injections
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Tablets and rings
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Product-related adverse events
Number of subjects: 277
Study: 27294814

Group type: EXPERIMENTAL
Intervention: Mozart music (Symphony No. 40 in g minor, KV 550)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Strauss music
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ABBA music
Number of subjects: 60

Group type: COMPARATOR
Intervention: Silence (control group)
Number of subjects: 60
Study: 24552320

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg) plus chemotherapy (cisplatin-paclitaxel or topotecan-paclitaxel)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Chemotherapy alone (cisplatin-paclitaxel or topotecan-paclitaxel)
Number of subjects: 452
Study: 23750033

Group type: EXPERIMENTAL
Intervention: Hypercaloric feeding (30% excess calories)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isocaloric feeding (matched energy expenditure)
Number of subjects: 8
Study: 19914003

Group type: EXPERIMENTAL
Intervention: Project SUCCESS intervention group
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study: 18435374

Group type: EXPERIMENTAL
Intervention: Ozone application for 10 seconds after etching and 10 seconds after bonding using a 5 mm delivery cup.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not subjected to ozone).
Number of subjects: 60
Study: 16518328

Group type: EXPERIMENTAL
Intervention: Regular ultrasound surveillance for graft stenosis every 4 months in addition to clinical monitoring
Number of subjects: 126

Group type: COMPARATOR
Intervention: Clinical monitoring alone
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Regular ultrasound surveillance for graft stenosis
Number of subjects: 126
Study: 12768330

Group type: EXPERIMENTAL
Intervention: DTPA-dGlu(1)-minigastrin
Number of subjects: 4

Group type: COMPARATOR
Intervention: DTPA-Leu(1)-minigastrin
Number of subjects: 4
Study: 10994679

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9180228

Group type: EXPERIMENTAL
Intervention: Surgical tube drain with primary wound closure
Number of subjects: 23

Group type: COMPARATOR
Intervention: Simple primary wound closure (no drain)
Number of subjects: 23
Study: 1621496

Group type: EXPERIMENTAL
Intervention: 2 mg morphine sulphate
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 0.02 mg fentanyl citrate
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 20 mg meperidine hydrochloride
Number of subjects: 43

Group type: COMPARATOR
Intervention: 2 ml saline
Number of subjects: 43
Study: 2418306

Group type: EXPERIMENTAL
Intervention: Intravenous nicardipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral nicardipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30334981

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate 4%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCMX 3%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propan-1-ol 60% (P-1)
Number of subjects: 0
Study: 28544215

Group type: EXPERIMENTAL
Intervention: Smooth neck implant (1.5 mm)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Rough neck implant with grooves
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Scalloped rough neck implant with grooves
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 93
Study: 26629926

Group type: EXPERIMENTAL
Intervention: Lactulose mannitol solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aspirin solution (600 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ascorbic acid solution (500 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Blackcurrant juice
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Various solutions (lactulose mannitol, aspirin, ascorbic acid, blackcurrant)
Number of subjects: 6
Study: 23489467

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 21399532

Group type: EXPERIMENTAL
Intervention: CHO + PRO (1% each of dextrose, fructose, and maltodextrin + 1.2% PRO)
Number of subjects: 14

Group type: COMPARATOR
Intervention: CHO (6% dextrose only)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CHO + PRO
Number of subjects: 14

Group type: COMPARATOR
Intervention: CHO
Number of subjects: 14
Study: 18855810

Group type: EXPERIMENTAL
Intervention: Topiramate (300 mg/day)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Naltrexone (50 mg/day)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 16790039

Group type: EXPERIMENTAL
Intervention: Minimal psychological intervention (MPI) administered by trained nurses
Number of subjects: 361

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Minimal psychological intervention (MPI)
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Economic evaluation of MPI
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Process evaluation of MPI
Number of subjects: 361
Study: 12681876

Group type: EXPERIMENTAL
Intervention: Misoprostol (400 microg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Gemeprost (1 mg)
Number of subjects: 90
Study: 11933303

Group type: EXPERIMENTAL
Intervention: Nimbus 3 alternating pressure mattress replacement system (APMRS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control surfaces (another APMRS in hospital, alternating pressure mattress overlay in nursing home)
Number of subjects: 32
Study: 8888329

Group type: EXPERIMENTAL
Intervention: 11 mg/day transdermal nicotine
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 22 mg/day transdermal nicotine
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 44 mg/day transdermal nicotine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Lower levels of nicotine replacement
Number of subjects: 71
Study: 1511080

Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI) 175-250 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI) + Lithium (Li) carbonate (serum level 0.5-0.9 mmol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6628802

Group type: EXPERIMENTAL
Intervention: Khellin treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 10
Study: 30249121

Group type: EXPERIMENTAL
Intervention: Live singing during hemodialysis (15 min for 6 sessions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard hemodialysis
Number of subjects: 24
Study: 29360560

Group type: EXPERIMENTAL
Intervention: Lidocaine dual-responsive in situ gel (2% lidocaine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 27160246

Group type: EXPERIMENTAL
Intervention: icosabutate 600 mg once daily
Number of subjects: 140

Group type: COMPARATOR
Intervention: control
Number of subjects: 140
Study: 24996489

Group type: EXPERIMENTAL
Intervention: Morning administration of controlled-release simvastatin 20 mg
Number of subjects: 122

Group type: COMPARATOR
Intervention: Evening administration of immediate-release simvastatin 20 mg
Number of subjects: 122
Study: 22913681

Group type: EXPERIMENTAL
Intervention: Eltrombopag (75 mg daily for 14 days)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 292
Study: 20353112

Group type: EXPERIMENTAL
Intervention: Point-to-point needling
Number of subjects: 92

Group type: COMPARATOR
Intervention: Perpendicular needling
Number of subjects: 92
Study: 18158849

Group type: EXPERIMENTAL
Intervention: Flavanol-rich grapeseed extract (FRGSE)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 16316352

Group type: EXPERIMENTAL
Intervention: Amino acid (AA) infusion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CAD patients
Number of subjects: 15
Study: 12525334

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study: 11174571

Group type: EXPERIMENTAL
Intervention: Clinical Diagnostic Criteria for Temporomandibular Disorders
Number of subjects: 163

Group type: COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI) diagnosis
Number of subjects: 163
Study: 9202909

Group type: EXPERIMENTAL
Intervention: Nasal midazolam (0.2 mg kg‐1, 5 mg ml‐1)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Rectal midazolam (0.3 mg kg‐1 in 5 mL saline)
Number of subjects: 95
Study: 7962441

Group type: EXPERIMENTAL
Intervention: Progesterone (1.0 micrograms/ml)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no progesterone)
Number of subjects: 14
Study: 3688927

Group type: EXPERIMENTAL
Intervention: pancuronium
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: pethidine
Number of subjects: 32
Study: 31347696

Group type: EXPERIMENTAL
Intervention: Constant time delay
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Most-to-least prompting
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Flexible prompt fading
Number of subjects: 27
Study: 29458392

Group type: EXPERIMENTAL
Intervention: GP mail‐outs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community engagement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: District nurse referrals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle Matters intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct contact with health professionals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Respondent‐driven sampling
Number of subjects: 0
Study: 27576169

Group type: EXPERIMENTAL
Intervention: Meditation retreat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxing on-site (vacation arm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular meditators
Number of subjects: 0
Study: 24786217

Group type: EXPERIMENTAL
Intervention: Internal cardioverter defibrillator-only therapy
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: S‐LVRR score (range, 0-7)
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 714
Study: 23715050

Group type: EXPERIMENTAL
Intervention: LCP‐Tacro once-daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Prograf twice-daily
Number of subjects: 47
Study: 20443101

Group type: COMPARATOR
Intervention: Pegylated interferon alfa 2b (1.5 microg/kg/week) alone (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa 2b (1.5 microg/kg/week) with ribavirin (12-15 mg/kg/day; group B)
Number of subjects: 40
Study: 18164145

Group type: EXPERIMENTAL
Intervention: Enhanced Services (nurse-delivered manual-guided behavioral drug and HIV risk reduction counseling and abstinence-contingent take-home buprenorphine)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard Services (physician administered advice and support, and weekly, non-contingent medication pick-up)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enhanced Services
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard Services
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 16192247

Group type: EXPERIMENTAL
Intervention: Latest CD4+ cell count <50 cells/mm3
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Viral load > or =100,000 copies/mL
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Latest CD4+ levels
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Latest viral load levels
Number of subjects: 432
Study: 12645830

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone combination (SFC) 50/100 microg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 100 microg twice daily plus oral montelukast (M) 10 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone combination (SFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) plus oral montelukast (M)
Number of subjects: 0
Study: 10665126

Group type: EXPERIMENTAL
Intervention: Intravenous/oral trovafloxacin (300 mg i.v. alatrofloxacin switching to 200 mg oral trovafloxacin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous imipenem/cilastatin switching to oral amoxycillin/clavulanic acid (1 g i.v. imipenem/cilastatin switching to 625 mg oral amoxycillin/clavulanic acid)
Number of subjects: 0
Study: 8626943

Group type: EXPERIMENTAL
Intervention: International normalized ratio < 2
Number of subjects: 3404

Group type: EXPERIMENTAL
Intervention: International normalized ratios between 2 and 3
Number of subjects: 3404

Group type: EXPERIMENTAL
Intervention: International normalized ratios between 3 and 4
Number of subjects: 3404

Group type: EXPERIMENTAL
Intervention: International normalized ratios between 4 and 5
Number of subjects: 3404

Group type: EXPERIMENTAL
Intervention: International normalized ratios > 5
Number of subjects: 3404
Study: 2054725

Group type: EXPERIMENTAL
Intervention: Polyacrylamide (Orcolon)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Sodium hyaluronate (Healon)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 137
Study: 31505974

Group type: EXPERIMENTAL
Intervention: Angle of Progression (AOP)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Head-Perineum Distance (HPD)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: AOP
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: HPD
Number of subjects: 221
Study: 30656870

Group type: EXPERIMENTAL
Intervention: Multilevel Guided Discharge Plan (MGDP)
Number of subjects: 960

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 960
Study: 28669324

Group type: EXPERIMENTAL
Intervention: Determine™ Combo (DETE)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: INSTI™ (INSTI)
Number of subjects: 17
Study: 27548757

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 82

Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 82
Study: 24973173

Group type: EXPERIMENTAL
Intervention: 2 FNA passes
Number of subjects: 62

Group type: COMPARATOR
Intervention: 4 FNA passes
Number of subjects: 62
Study: 21830844

Group type: EXPERIMENTAL
Intervention: Benazepril + Amlodipine (B+A)
Number of subjects: 10506

Group type: EXPERIMENTAL
Intervention: Benazepril + Hydrochlorothiazide (B+H)
Number of subjects: 10506
Study: 20340049

Group type: EXPERIMENTAL
Intervention: Short-stay intensive care treatment (SSIC, 8 h of intensive care stay)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Control treatment (care as usual, overnight intensive care stay)
Number of subjects: 410
Study: 17157478

Group type: EXPERIMENTAL
Intervention: Diflunisal 1000 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lornoxicam 16 mg
Number of subjects: 40
Study: 16382589

Group type: EXPERIMENTAL
Intervention: Fuji IX GP Fast
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ketac‐Molar Maxicap
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (uncontaminated)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dentin contaminated with saliva (Group 2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dentin contaminated, washed and air dried (Group 3)
Number of subjects: 90
Study: 12423478

Group type: EXPERIMENTAL
Intervention: Music played to fetuses via headphone on maternal abdomen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (headphone without sound)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prenatal music exposure
Number of subjects: 20
Study: 10684124

Group type: EXPERIMENTAL
Intervention: Mixed tea (3 g/day orally and 0.1% smeared on mucosa lesions three times a day for 3 months and 6 months)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7657919

Group type: EXPERIMENTAL
Intervention: Carbamazepine (300 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 2617212

Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate 500 mg t.i.d. for 1 week
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Erythromycin stearate 500 mg t.i.d. for 1 week
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 12
Study: 348537

Group type: EXPERIMENTAL
Intervention: Otocerol
Number of subjects: 106

Group type: COMPARATOR
Intervention: Cerumol
Number of subjects: 106
Study: 31774037

Group type: EXPERIMENTAL
Intervention: Vorapaxar 2.5 mg per day for 12 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31273244

Group type: EXPERIMENTAL
Intervention: Intranasal AVP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 0
Study: 28714431

Group type: EXPERIMENTAL
Intervention: Lens cleaning paper patching
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122
Study: 25689743

Group type: EXPERIMENTAL
Intervention: High-fiber AXOS (15 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fiber FLAX (15 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-fiber (4 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-fiber isocaloric (LF-iso)
Number of subjects: 0
Study: 23751992

Group type: EXPERIMENTAL
Intervention: 2 L PEG plus ascorbic acid (PEG+Asc)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 4 L PEG plus simethicon (PEG+Sim)
Number of subjects: 120
Study: 22126115

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) program plus usual care
Number of subjects: 228

Group type: COMPARATOR
Intervention: Psycho-education program plus usual care
Number of subjects: 228

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 228
Study: 19447387

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) treatment
Number of subjects: 18645

Group type: COMPARATOR
Intervention: Non-EPA treatment
Number of subjects: 18645
Study: 17431702

Group type: EXPERIMENTAL
Intervention: Albumin therapy (40 g or 80 g within 24 h from symptom onset)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Albumin therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 49
Study: 14704548

Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride 0.01%
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (latanoprost arm)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (timolol arm)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bunazosin hydrochloride 0.01% (latanoprost group)
Number of subjects: 120
Study: 11534537

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 9273030

Group type: EXPERIMENTAL
Intervention: Transconjunctival injection
Number of subjects: 46

Group type: COMPARATOR
Intervention: Transcutaneous injection
Number of subjects: 46
Study: 8484970

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus danazol
Number of subjects: 183

Group type: COMPARATOR
Intervention: Tamoxifen plus placebo
Number of subjects: 183
Study: 3119785

Group type: EXPERIMENTAL
Intervention: 18 or 24 Gy of radiation therapy (RT) to craniospinal plus abdominal RT including the ovaries
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 18 or 24 Gy of radiation therapy (RT) to craniospinal RT
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 18 or 24 Gy of radiation therapy (RT) to cranial RT
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Craniospinal plus abdominal RT
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Craniospinal RT
Number of subjects: 97
Study: 30768490

Group type: EXPERIMENTAL
Intervention: High entry sCD163
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: High 6-month post-ART sCD163
Number of subjects: 67
Study: 28774856

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modafinil 3.2 mg/kg (in mice)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modafinil 10 mg/kg (in mice)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modafinil 32 mg/kg (in mice)
Number of subjects: 0
Study: 26201229

Group type: EXPERIMENTAL
Intervention: Fluoride-containing adhesive (One-up Bond F Plus - OP)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: MDPB and fluoride-containing adhesive (Clearfil Protect Bond - PB)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (enamel and dentin blocks without adhesive)
Number of subjects: 17
Study: 23608567

Group type: EXPERIMENTAL
Intervention: Negatively aspheric IOL (Acri.Smart 36A)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Aspherically neutral IOL (Akreos MI‐60)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional spherical hydrophobic IOL (Acrysof SN60AT)
Number of subjects: 2
Study: 22189151

Group type: EXPERIMENTAL
Intervention: Polyalkylamide gel (PAIG) treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Delayed PAIG injections (12 weeks later)
Number of subjects: 36
Study: 19327074

Group type: EXPERIMENTAL
Intervention: Family/Adolescent-Centered (FACE) Advance Care Planning intervention
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (Developmental History, Health Tips, Future Plans)
Number of subjects: 38
Study: 16702866

Group type: EXPERIMENTAL
Intervention: OPTI‐FREE Express
Number of subjects: 8

Group type: COMPARATOR
Intervention: ReNu MultiPlus
Number of subjects: 8
Study: 15740172

Group type: EXPERIMENTAL
Intervention: Antenatal care intervention
Number of subjects: 0
Study: 11740191

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Indinavir
Number of subjects: 34